Skip to main content

Advertisement

SpringerLink
Log in

Antiretroviral-associated hepatotoxicity

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

The use of highly active antiretroviral therapy has dramatically reduced HIV-associated morbidity and mortality. As a result, patients are often being treated longer and with more complex medical regimens than ever before, increasing the risk for drug interactions and toxicities. In particular, hepatotoxicity caused by antiretroviral use has become an increasingly appreciated potential complication of drug treatment. All classes of antiretrovirals have been reported to induce liver enzyme abnormalities. However, certain antiretrovirals appear much more likely to be associated with druginduced hepatotoxicity. The risk of antiretroviral-related hepatotoxicity may be associated with patient-specific risk factors, including pre-existing viral hepatitis, baseline elevated liver function test results, female gender, and substance abuse. In addition, complex drug-drug interactions may potentate the risk of antiretroviral-associated hepatotoxicity. Coinfection with hepatitis B or hepatitis C appears to increase the risk of antiretroviral-related hepatotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860.

    Article  PubMed  Google Scholar 

  2. Puoti M, Torti C, Ripamonti D, et al.: HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003, 32:259–267.

    Article  PubMed  Google Scholar 

  3. Ogedegbe AO, Sulkowski MS: Antiretroviral-associated liver injury. Clin Liver Dis 2003, 7:475–499.

    Article  PubMed  Google Scholar 

  4. Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492–497.

    Article  PubMed  CAS  Google Scholar 

  5. Dieterich D: Managing antiretroviral-associated liver disease.J Acquir Immune Defic Syndr 2003, 34(Suppl 1):S34-S39.

    PubMed  Google Scholar 

  6. Pol S, Lebray P, Vallet-Pichard A: HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis 2004, 38(Suppl 2):S65-S72.

    Article  PubMed  CAS  Google Scholar 

  7. Nierenberg DW: “Did this drug cause my patient’s hepatitis?” and related questions. Ann Intern Med 2002, 136:480–483.

    PubMed  Google Scholar 

  8. Sabin CA: Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis 2004, 38(Suppl2):S56-S64.

    Article  PubMed  Google Scholar 

  9. Becker S: Liver toxicity in epidemiological cohorts.Clin Infect Dis 2004, 38(Suppl 2):S49-S55. This is a nice review of important cohort studies that have reported risk factors associated with increased risk of hepatotoxicity.

    Article  PubMed  Google Scholar 

  10. Dieterich DT, Robinson PA, Love J, et al.: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004, 38(Suppl2):S80-S89. This is an excellent discussion of NNRTI-associated hepatotoxicity and supporting evidence.

    Article  PubMed  CAS  Google Scholar 

  11. Kontorinis N, Dieterich DT: Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003, 23:173–182.

    Article  PubMed  CAS  Google Scholar 

  12. Manfredi R, Calza L, Chiodo F: Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr 2004, 35:492–502.

    Article  PubMed  CAS  Google Scholar 

  13. Stern JO, Robinson PA, Love J, et al.: Nevirapine hepatic safety project. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, July 7–12, 2002.

  14. Shepard K: Clarification of risk factors for severe, life threatening and fatal hepatotoxicity with Viramune (nevirapine) [letter]. Rigdefield, CT: Boehringer Ingelheim Pharmaceuticals; 2004.

    Google Scholar 

  15. Patel SM, Johnson S, Belknap SM: Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Aquir Immune Defic Syndr 2004, 35:120–125.

    Article  CAS  Google Scholar 

  16. For the PACTG 1022 Study Team: Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG1022. J Acquir Immune Defic Syndr 2004, 36:772–776.

    Article  Google Scholar 

  17. Gonzalez D, Jiménez-Nácher I, Romero M, et al.: Changes in nevirapine plasma concentrations along 48 weeks and relationship with transaminase elevations [abstract 856]. AntivirTher 2003, (Suppl 1):S425.

  18. Geel J, Pitt J, Orrell CJ, et al.: The effect of fluconazole on nevirapine pharmacokinetics [abstract WeOr1239]. Program and abstracts of the XV International AIDS Conference. Bangkok, Thailand, July 11–16, 2004.

  19. Almond LM, Boffito M, Hoggard PG, et al.: The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004, 20:716–722.

    Article  PubMed  CAS  Google Scholar 

  20. Dailly E, Billaud E, Reliquet V, et al.: No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 2004, 60:343–348.

    Article  PubMed  CAS  Google Scholar 

  21. Mallal S, Martin A, Cameron P, et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 *0101 abrogated by low CD4+ T cell counts. Program and abstracts of the XV International AIDS Conference. Bangkok, Thailand, July 11–16, 2004.

  22. Sulkowski MS: Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.Clin Infect Dis 2004, 38(Suppl 2):S90-S97. This is a recent and comprehensive review of PI-related hepatotoxicity.

    Article  PubMed  CAS  Google Scholar 

  23. Sulkowski MS: Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003, 23:183–194.

    Article  PubMed  CAS  Google Scholar 

  24. Sulkowski MS, Mehta SH, Chaisson RE, et al.: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004, 18:2277–2284.

    Article  PubMed  CAS  Google Scholar 

  25. Montessori V, Harris M, Montaner JS: Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis 2003, 23:167–172.

    Article  PubMed  CAS  Google Scholar 

  26. Montaner JS, Cote HC, Harris M, et al.: Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA.Clin Infect Dis 2004, 38(Suppl 2):S73-S79.

    Article  PubMed  CAS  Google Scholar 

  27. Braitstein P, Palepu A, Dieterich D, et al.: Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS 2004, 18:2221–2234.

    Article  PubMed  Google Scholar 

  28. Bonacini M: Liver injury during highly active antiretroviral therapy: the effect of hepatitis C co-infection. Clin Infect Dis 2004, 38(Suppl 2):S104-S108.

    Article  PubMed  CAS  Google Scholar 

  29. French AL, Benning L, Anastos K, et al.: Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis coinfection. Clin Infect Dis 2004, 39:402–410.

    Article  PubMed  CAS  Google Scholar 

  30. Uberti-Foppa C, De Bona A, Morsica G, et al.: Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 33:146–152.

    Article  PubMed  Google Scholar 

  31. Macias J, Castellano V, Merchante N, et al.: Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004, 18:767–774.

    Article  PubMed  CAS  Google Scholar 

  32. Aranzabal L, Casado JL, Moya J, et al.: HAART-associated hepatotoxicity in HIVJHCV co-infected patients: the role of liver histologic damage and drug levels [abstract PL14.1]. Program and abstracts from the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, November 14–18, 2004.

  33. Soriano V, Massimo P, Sulkowski, et al.: Care of patients with hepatitis C and HIV co-infection. AIDS 2004, 18:1-12. 34. Powderly WG: Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits.Clin Infect Dis 2004, 38(Suppl 2):S109-S113. This is a very useful discussion that brings to light important therapeutic considerations when treating HIV in coinfected patients.

    Google Scholar 

  34. Powderly WG: Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. Clin Infect Dis 2004, 38(Suppl 2):S109-S113. This is a very useful discussion that brings to light important thera-peutic considerations when treating HIV in coinfected patients.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Roche Laboratories Inc., 340 Kingsland Street, 07110, Nutley, NJ, USA

    Kendra D. Kress PharmD

Authors
  1. Kendra D. Kress PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kress, K.D. Antiretroviral-associated hepatotoxicity. Curr Infect Dis Rep 7, 103–107 (2005). https://doi.org/10.1007/s11908-005-0068-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-005-0068-z

Keywords

Search

Navigation